Page 2 - Hepatitisc Virus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NanoViricides, Inc : NanoViricides Bolsters Partnership Efforts

SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it has engaged

United statesAagami incStrategic consulting servicesBusiness research market intelligence servicesExchange commissionDevices technologyNanoviricides incDrug administrationSecurities exchangeCommittee for medicinal products humanEuropean medicines agencyTheracour pharma incTechnology licensing servicesBusiness developmentOral syrupOral gummies

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A.

United statesJean pierre sommadossiJonae barnesQi huangAlina jucovAtea pharmaceuticals incGlobenewswire incCorporate communicationsAtea pharmaceuticalsEuropean association for the studyWhile the companyInclude new antiviral efficacy resultsLead in cohortOngoing phaseAlso highlightHigh prevalence

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-In-Class Combination Profile Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also H

United statesAlina jucovQi huangJonae barnesJean pierre sommadossiCorporate communicationsWhile the companyAtea pharmaceuticalsAtea pharmaceuticals incFounder of atea pharmaceuticals weInclude new antiviral efficacy resultsLead in cohortOngoing phaseAlso highlightHigh prevalenceResistance associated substitutions

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Po

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of N.

United statesPalivizumab synagisSecurities exchangeCommittee for medicinal products humanDrug administrationTheracour pharma incExchange commissionEuropean medicines agencyNanoviricides incBroad spectrum antiviralStrong activity againstHuman immunodeficiency virusHepatitisb virusHepatitisc virusHerpes simplex virusVaricella zoster virus

NanoViricides, Inc : NanoViricides Has Filed its Quarterly Report

NanoViricides, Inc : NanoViricides Has Filed its Quarterly Report
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Tamil naduUnited statesCommittee for medicinal products humanNanoviricides platform technologyExchange commissionSecurities exchangeNanoviricides incEuropean medicines agencyDrug administrationTheracour pharma incKarveer meditech pvt ltdQuarterly reportUnique drug candidateBroad spectrum antiviral activity poisedViral infections reminiscentBroad spectrum antibacterial activity